Animal Models (Cytokine Therapy)

CD40L Improves Survival after HSV-1 Infection in BMT

Published in Proteomics Weekly, December 21st, 1998

CD40 ligand treatment improved posttransplant survival after herpes simplex virus-1 (HSV-1) infection, in an animal study.

Posttransplant infection associated with host immune deficiency is a primary cause of nonrelapse mortality in human bone marrow transplant recipients, noted Janice L. Beland, Harvard Medical School, Boston, Massachusetts, and colleagues.

Beland et al. developed a murine model of posttransplant infection in which allogeneic bone marrow transplant recipients were infected with HSV-1 by intraperitoneal inoculation 12 weeks posttransplant ("Recombinant CD40L Treatment Protects Allogeneic Murine Bone Marrow Transplant Recipients from...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Proteomics Weekly

Source: Proteomics Weekly (1998-12-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry